• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down0.26% Nasdaq Down0.34%

    Celldex Therapeutics, Inc. (CLDX)

    -NasdaqGS
    25.48 Up 1.13(4.64%) Jul 6, 4:00PM EDT
    Add to Portfolio
    ProfileGet Profile for:
    Celldex Therapeutics, Inc.
    Perryville III Building
    Suite 200
    Hampton, NJ 08827
    United States - Map
    Phone: 908-200-7500
    Fax: 908-454-1911
    Website: http://www.celldextherapeutics.com

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Biotechnology
    Full Time Employees:156

    Business Summary 

    Celldex Therapeutics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes novel therapeutics for human health care in the United States. The company’s lead drug candidates comprise rindopepimut (CDX-110), a targeted immunotherapeutic in a pivotal Phase III study for the treatment of front-line glioblastoma, as well as in Phase II study for the treatment of recurrent glioblastoma; and Glembatumumab vedotin (CDX-011), a targeted antibody-drug conjugate in a randomized Phase IIb study for the treatment of triple negative breast cancer, as well as in Phase II study for the treatment of metastatic melanoma. It also has various earlier stage drug candidates in clinical development, including varlilumab (CDX-1127), a fully human therapeutic monoclonal antibody for cancer indications; CDX-1401, a targeted immunotherapeutic aimed at antigen presenting cells for cancer indications; and CDX-301, an immune cell mobilizing agent and dendritic cell growth factor. The company’s preclinical product candidate includes CDX-014, a fully-human monoclonal antibody-drug conjugate that targets T-cell TIM-1, a molecule, which is upregulated in various cancers comprising renal cell and ovarian carcinomas. It has research collaboration and license agreements with Medarex, Inc.; Rockefeller University; Duke University Brain Tumor Cancer Center; Ludwig Institute for Cancer Research; Alteris Therapeutics, Inc.; University of Southampton; Amgen Inc.; Amgen Fremont; and Seattle Genetics, Inc., as well as clinical trial collaboration with Roche Holding, Bristol-Myers Squibb Company, and Oncothyreon Inc. The company is headquartered in Hampton, New Jersey.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Celldex Therapeutics, Inc.

    Corporate Governance 
    Celldex Therapeutics, Inc.’s ISS Governance QuickScore as of Jun 1, 2015 is 2. The pillar scores are Audit: 2; Board: 5; Shareholder Rights: 1; Compensation: 6.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
     PayExercised
    Mr. Anthony S. Marucci M.B.A., 53
    Chief Exec. Officer, Pres and Director
    879.00K0.00
    Dr. Tibor Keler Ph.D., 56
    Exec. VP, Founder and Chief Scientific Officer
    546.00K0.00
    Mr. Avery W. Catlin , 67
    Chief Financial Officer, Principal Accounting Officer, Sr. VP, Treasurer and Sec.
    424.00K110.00K
    Dr. Thomas Davis M.D. , 51
    Chief Medical Officer and Exec. VP
    565.00K0.00
    Dr. Ronald A. Pepin Ph.D., 59
    Chief Bus. Officer and Sr. VP
    425.00K0.00
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders